Tomonari Kunihisa

Tomonari Kunihisa

Auto-generated profile, based on publicly available information

Tomonari Kunihisa

Division of Breast Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in JCIS Open
Verified
Journal Article
Open access
CWChihiro Wakayama
Chihiro Wakayama
SISachiko Inubushi
Sachiko Inubushi
TKTomonari Kunihisa
Tomonari Kunihisa
SMSachiko Mizumoto
Sachiko Mizumoto
MBMotoi Baba
Motoi Baba
Tooru OoyaTooru Ooya
Tooru Ooya

1 November 2023 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
SMSachiko Mizumoto
Sachiko Mizumoto
SISachiko Inubushi
Sachiko Inubushi
MMMayuko Miki
Mayuko Miki
HNHaruna Nakamura
Haruna Nakamura
MBMotoi Baba
Motoi Baba
TKTomonari Kunihisa
Tomonari Kunihisa
Background/Aim: Breast cancer that is estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor-2 (HER2)-negative is termed triple-negative breast cancer (TNBC). Cytotoxic chemotherapy remains the first choice of treatment against TNBC due to lack of specific therapeutic targets. TNBC is not classified based on therapeutic targets, but recently, the development of targeted therapies – including immune checkpoint inhibitors and poly (adenosine diphosphate–ribose) polymerase inhibitors – has gained attention. This study aimed to examine a novel target-oriented TNBC classification to further facilitate targeted therapy by classifying TNBC based on the breast cancer 1 (BRCA1)-like as well as the protein expression of HER2, programmed death ligand 1 (PD-L1), androgen receptor (AR), cytokeratin 5/6, and epidermal growth factor receptor (EGFR). Patients and Methods: We enrolled 17 patients with primary TNBC who did not receive preoperative chemotherapy and underwent surgery at the Kobe University Hospital, Japan, between January 1, 2018, and July 31, 2019. Immunohistochemical staining was performed on tumor specimens, while a BRCAness test was performed using multiplex ligation-dependent probe amplification (MLPA) analysis. A BRCAness score 0.5 or higher was considered BRCA1-like. Results: Tumors were classified as HER2-low (immunohistochemistry score 1+ or 2+ and FISH negative), PD-L1 positive, AR positive, or BRCA1-like. HER2-low, PD-L1 positive, AR positive, and BRCA1-like were detected in 11 (64.7%), 4 (23.5%), 6 (35.3%), and 6 (35.3%) samples. The tumor of only one patient could not be classified into any of these categories. Conclusion: Almost all TNBC cases can be classified according to treatable targets.


26 September 2025 in Anticancer Research
Verified
Journal Article
Open access
PDF file
SIShotaro Inoue
Shotaro Inoue
MMMayuko Miki
Mayuko Miki
SMSachiko Mizumoto
Sachiko Mizumoto
MYMayuko Yamamoto
Mayuko Yamamoto
MBMotoi Baba
Motoi Baba
SISachiko Inubushi
Sachiko Inubushi
Background/Aim: Patient-derived xenograft (PDX) and Patient-derived orthotopic xenograft (PDOX) models are considered to recapitulate the heterogeneity and biological characteristics of original tumors more faithfully than conventional models. This study aimed to evaluate the extent to which specific tumor markers are retained in PDOX models of triple-negative breast cancer (TNBC), in comparison with their corresponding patient tumors. Materials and Methods: PDOX models were established by orthotopically implanting tumor tissues from 15 TNBC patients into the mammary fat pads of immunodeficient mice. Immunohistochemical analyses were performed for CK5/6, HER2, EGFR, androgen receptor (AR), and Trop-2 in both the patient tumors and their corresponding PDOX tissues to evaluate the concordance of molecular marker expression. Results: Trop-2 expression was consistently preserved across all tumor PDOX models. EGFR expression was preserved. In contrast, AR expression was observed in two of the original tumors, but it was completely lost in the corresponding PDOX models. CK5/6 and HER2 showed variable preservation. Conclusion: TNBC PDOX models are promising tools for preclinical drug evaluation; however, variability in the retention of molecular targets, such as AR, CK5/6, and HER2, emphasizes the importance of verifying marker expression prior to functional analysis. Tumor heterogeneity and clonal selection during engraftment may contribute to these discrepancies.

30 March 2022 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
MYMayuko Yamamoto
Mayuko Yamamoto
TKTomonari Kunihisa
Tomonari Kunihisa
MBMotoi Baba
Motoi Baba
SMSachiko Mizumoto
Sachiko Mizumoto
YYYuji Yamashita
Yuji Yamashita
HTHirokazu Tanino
Hirokazu Tanino
A 56-year-old female patient with left breast cancer presented at our hospital. Preoperative CT scan showed an isolated bilateral pectoralis major muscle defect and abnormal muscle originating from the entire sternum and inserting in the lower ribs and rectus sheath. Total mastectomy and axillary lymph node dissection were performed. We believe that this case is unique and that others like it have never been reported. If there is a defect in the pectoralis major muscle, reconstructive surgery with a tissue expander is contraindicated. Therefore, preoperative evaluation of the chest wall musculature on imaging is recommended.

24 May 2023 in Research Square
Verified
Preprint
Open access
PDF file
HNHaruna Nakamura
Haruna Nakamura
SMSachiko Mizumoto
Sachiko Mizumoto
HTHirokazu Tanino
Hirokazu Tanino
YNYui Niwa
Yui Niwa
MOMitsutoshi Ogino
Mitsutoshi Ogino
TKTomonari Kunihisa
Tomonari Kunihisa
Background: Some germline pathogenic variants (PVs) have been observed with high frequency in certain regions and races and are called founder mutations. Founder mutations in BRCA1/2 genes have rarely been reported in Japan. At Kakogawa Central City Hospital, BRCA2 c.5576_5579del accounted for approximately 70% of PVs detected by BRCA1/2 genetic testing. Therefore, we conducted a retrospective observational study to investigate its distribution in Hyogo Prefecture. Patients and Methods: This study was conducted at Kobe University Hospital and three collaborating institutions. Breast cancer patients with germline PVs detected by BRCA1/2 genetic testing between July 1, 2018 and March 31, 2021 were included. The clinical characteristics and breast cancer subtypes were compared between carriers of BRCA2c.5576_5579del and those of other PVs. The detection rate of BRCA2c.5576_5579del was also compared with that observed in a previous report. Results: A total of 38 breast cancer patients were included; 14 of them underwent testing for companion diagnosis to poly ADP-ribose polymerase inhibitor treatment and 24 underwent testing for diagnosis of hereditary breast and ovarian cancer. PVs in BRCA1 andBRCA2 were detected in 12 and 26 patients, respectively, 12 of whom were BRCA2c.5576_5579del carriers. There were no clinicopathological differences between BRCA2PV carriers and BRCA2 c.5576_5579del carriers. BRCA2c.5576_5579del accounted for 30.8% of the PVs detected, with a particularly high frequency of 72.7% at Kakogawa Central City Hospital. Conclusion: Our study revealed a strong founder effect for BRCA2 c.5576_5579del in breast cancer patients in Hyogo Prefecture, especially in Kakogawa City. In the future, a survey of the distribution of the BRCA2 c.5576_5579del carriers may provide more clarity regarding their localization.